Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Extrasynaptic delta-containing GABA-A receptors are a specialized subclass of ligand-gated ion channels located outside the synaptic cleft, typically composed of alpha-4 or alpha-6, beta, and delta subunits (Brickley & Mody, 2012, Nature Reviews Neuroscience). Unlike synaptic receptors that mediate rapid phasic inhibition, these receptors respond to low concentrations of ambient GABA to provide a persistent tonic inhibitory current that regulates the baseline excitability of neurons (Belelli et al., 2009, Journal of Neuroscience). They are uniquely sensitive to endogenous neurosteroids, such as allopregnanolone, which act as potent positive allosteric modulators (Maguire & Mody, 2008, Neuron). This sensitivity makes them critical in the pathophysiology of mood disorders, particularly postpartum depression, where neurosteroid levels fluctuate significantly (Meltzer-Brody et al., 2018, The Lancet). Pharmacological targeting of these receptors with synthetic neurosteroids like brexanolone and zuranolone has proven effective in treating depressive symptoms by restoring inhibitory tone (Gunduz-Bruce et al., 2019, NEJM). Additionally, these receptors are implicated in epilepsy and alcohol use disorders, serving as a distinct therapeutic target from traditional benzodiazepine-sensitive synaptic GABA-A receptors (Whiting, 2003, Drug Discovery Today).
Positive allosteric modulation of extrasynaptic GABA-A receptors to enhance tonic chloride conductance and reduce neuronal over-excitability.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor delta subunit-containing receptor (delta-GABAAR) (delta-GABAAR).